ArticleFrontiers in public health2022

Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.

Kaiyu Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.